Status:
COMPLETED
MRD Detection by NGS in Pediatric T-ALL
Lead Sponsor:
The Children's Hospital of Zhejiang University School of Medicine
Conditions:
Acute Lymphoblastic Leukemia, Pediatric
Eligibility:
All Genders
1-18 years
Brief Summary
This retrospective analysis aims to investigate pediatric patients with T cell acute lymphoblastic leukemia who were detected for minimal residual disease (MRD) using next-generation sequencing (NGS)....
Detailed Description
This was a prospective, single-center, observational study conducted in children with ALL between February 2018 and December 2022. Children with newly diagnosed T-ALL who undergone NGS of T-cell recep...
Eligibility Criteria
Inclusion
- Children with newly diagnosed T-ALL who undergone NGS of T-cell receptors
Exclusion
- T-ALL patients who have not undergone high-throughput sequencing.
- T-ALL Patients without traceable significant clones.
Key Trial Info
Start Date :
February 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2022
Estimated Enrollment :
69 Patients enrolled
Trial Details
Trial ID
NCT06525116
Start Date
February 1 2018
End Date
December 31 2022
Last Update
July 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Children's Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310003